Affiliation:
1. “D.V. Sokolskiy Institute of Fuel, Catalysis and Electrochemistry” JSC, Almaty 050010, Kazakhstan
2. Faculty of Chemistry and Chemical Technology, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan
3. Laboratory for Genetic Engineering, RSE “National Center for Biotechnology”, Astana 010000, Kazakhstan
4. Department of Biochemical Engineering, International Engineering Technological University, Almaty 050040, Kazakhstan
Abstract
In Central Eurasia, the availability of drugs that are inhibitors of the SARS-CoV-2 virus and have proven clinical efficacy is still limited. The aim of this study was to evaluate the activity of drugs that were available in Kazakhstan during the acute phase of the epidemic against SARS-CoV-2. Antiviral activity is reported for Favipiravir, Tilorone, and Cridanimod, which are registered drugs used for the treatment of respiratory viral infections in Kazakhstan. A licorice (Glycyrrhiza glabra) extract was also incorporated into this study because it offered an opportunity to develop plant-derived antivirals. The Favipiravir drug, which had been advertised in local markets as an anti-COVID cure, showed no activity against SARS-CoV-2 in cell cultures. On the contrary, Cridanimod showed impressive high activity (median inhibitory concentration 66 μg/mL) against SARS-CoV-2, justifying further studies of Cridanimod in clinical trials. Tilorone, despite being in the same pharmacological group as Cridanimod, stimulated SARS-CoV-2 replication in cultures. The licorice extract inhibited SARS-CoV-2 replication in cultures, with a high median effective concentration of 16.86 mg/mL. Conclusions: The synthetic, low-molecular-weight compound Cridanimod suppresses SARS-CoV-2 replication at notably low concentrations, and this drug is not toxic to cells at therapeutic concentrations. In contrast to its role as an inducer of interferons, Cridanimod is active in cells that have a genetic defect in interferon production, suggesting a different mechanism of action. Cridanimod is an attractive drug for inclusion in clinical trials against SARS-CoV-2 and, presumably, other coronaviruses. The extract from licorice shows low activity against SARS-CoV-2. At the same time, high doses of 2 g/kg of this plant extract show little or no acute toxicity in animal studies; for this reason, licorice products can still be considered for further development as a safe, orally administered adjunctive therapy.
Funder
Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan
Subject
Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science
Reference41 articles.
1. COVID-19 in Kazakhstan: Economic consequences and policy implications;Ybrayev;CAP PAPER,2020
2. (2023, August 04). COVID-19 Crisis Response in Central Asia. Available online: https://www.oecd.org/coronavirus/policy-responses/covid-19-crisis-response-in-central-asia-5305f172/.
3. (2023, August 04). Electronic Source. Available online: https://covid19.trackvaccines.org/country/kazakhstan/.
4. Effectiveness of social distancing interventions in containing COVID-19 incidence: International evidence using Kalman filter;Prakash;Econ. Hum. Biol.,2022
5. Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models;Takeshita;iScience,2022